FOLH1 and prostate cancer: Kloss et al. (2018) designed anti-PSMA CAR-T cells to express a dominant negative TGFβ-receptor II (TGFβRII) and investigated the activity of these cells against a prostate cancer cell line and in a mouse model of prostate cancer [172].